SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV

被引：6
|
作者：
Sulkowski, M. [1 ]
Bourliere, M. [2 ]
Bronowicki, J. -P. [3 ]
Streinu-Cercel, A. [4 ]
Preotescu, L. [4 ]
Asselah, T. [5 ]
Pawlotsky, J. -M. [6 ]
Shafran, S. [7 ]
Pol, S. [8 ]
Caruntu, F. A. [4 ]
Mauss, S. [9 ]
Larrey, D. [10 ]
Haefner, C. [11 ]
Datsenko, Y. [11 ]
Stern, J. [12 ]
Kubiak, R. [11 ]
Steinmann, G. [11 ]
机构：
[1] Johns Hopkins Univ, Dept Viral Hepatitis, Baltimore, MD USA
[2] Hop St Joseph, Marseille, France
[3] Hop Brabois, Vandoeuvre Les Nancy, France
[4] Prof Dr Matei Bals Inst Infect Dis 1, Bucharest, Romania
[5] Hop Beaujon, Clichy, France
[6] Hop Henri Mondor, F-94010 Creteil, France
[7] Univ Alberta, Edmonton, AB, Canada
[8] Hop Cochin, F-75674 Paris, France
[9] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany
[10] Hop St Eloi, Montpellier, France
[11] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[12] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
来源：
JOURNAL OF HEPATOLOGY | 2010年 / 52卷
关键词：
D O I：
10.1016/S0168-8278(10)61191-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S462 / S463
页数：2
相关论文
共 50 条
  • [21] Impact of baseline (BL) HCV RNA to predict treatment outcome in HCV genotype 2 and 3 patients receiving peginterferon (PegIFN) alfa-2a (40KD)/ribavirin (RBV): analysis of data from the multinational PROPHESYS cohorts
    Shiffman, Mitchell L.
    Parruti, Giustino
    Ferenci, Peter
    Gschwantler, Michael
    De Bartolomeo, Giuseppe
    Passariello, Nicola
    Caruntu, Florin A.
    Horban, Andrzej
    Lengyel, Gabriella
    Schmitz, Manuela
    Golotta, Caterina
    Tatsch, Fernando
    HEPATOLOGY, 2012, 56 : 575A - 575A
  • [22] Viral Response at Week 2 as a Predicitive Factor for Rvr in Chronic Hepatitis C Genotype 1 Infection Treated With Peginterferon Alfa-2A (PEG) and Ribavirin (RBV)
    Mauss, Stefan
    Lutz, Thomas
    Boeker, Klaus H.
    Link, Ralph
    Moog, Gero
    Stoehr, Albrecht D.
    Baumgarten, Axel
    Heyne, Renate
    Eisenbach, Christoph
    Teuber, Gerlinde
    Weber, Bernd
    Schott, Eckart
    Hillenbrand, Heribert
    Alshuth, Ulrich
    Hueppe, Dietrich
    Buggisch, Peter
    GASTROENTEROLOGY, 2012, 142 (05) : S958 - S958
  • [23] CLINICAL UTILITY OF THE REALTIME HCV ASSAY (ABBOTT MOLECULAR) FOR RESPONSE-GUIDED THERAPY IN PATIENTS INFECTED WITH HCV GENOTYPES 1, 2, OR 3 AND TREATED WITH PEGINTERFERON-ALFA PLUS RIBAVIRIN (PEGIFN/RBV)
    Vermehren, Johannes
    Yu, Ming-Lung
    Monto, Alexander
    Yao, Joseph D.
    Anderson, Christopher
    Bertuzis, Rasa
    Schneider, George
    Sarrazin, Christoph
    HEPATOLOGY, 2010, 52 (04) : 789A - 790A
  • [24] EFFECT OF HIGH-DOSE RIBAVIRIN (RBV), ALINIA (NITAZOXANIDE) AND PEGYLATED INTERFERON (PEGIFN) ALFA-2A IN ATTAINING SUSTAINED VIROLOGIC RESPONSE (SVR) IN TREATMENT OF CHRONIC HEPATITIS C
    Basu, P.
    Rayapudi, K.
    Shah, N. J.
    Pacana, T.
    Krishnaswamy, N.
    Brown, R., Jr.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S102 - S102
  • [25] Optimized virological response in genotype 4 chronic hepatitis C patients treated with peginterferon alfa-2A (40KD) (PEGASYS®) in combination with ribavirin (RBV).
    Diago, M
    Hadziyannis, SJ
    Dunant, H
    Bodenheimer, H
    Hassanein, T
    Uchman, S
    Marcellin, P
    Ramadori, G
    Delwaide, J
    Sedarati, F
    HEPATOLOGY, 2002, 36 (04) : 364A - 364A
  • [26] Sustained virological response (SVR) rate of 67% in HCV genotype 1-infected prior null responders treated with danoprevir/ritonavir (DNVr) in combination with peginterferon alfa-2a (40KD) plus ribavirin (PegIFNα-2a/RBV)
    Gane, Edward J.
    Rouzier, Regine
    Wiercinska-Drapalo, Alicia
    Larrey, Dominique G.
    Bhardwaj, Rajinder
    Brennan, Barbara J.
    Giraudon, Mylene
    Le Pogam, Sophie
    Najera, Isabel
    Petric, Rosemary
    Jonathan Tran
    Zhang, Ying
    Smith, Patrick F.
    Yetzer, Ellen S.
    Shulman, Nancy
    HEPATOLOGY, 2012, 56 : 558A - 558A
  • [27] PEGINTERFERON ALFA-2A (40KD) (PEGIFNα2A) HAS A WIDE SAFETY MARGIN IN COMBINATION WITH RIBAVIRIN (RBV) 1000/1200 MG/DAY IN PATIENTS INFECTED WITH HCV GENOTYPE 1: POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED MULTICENTER STUDIES
    Marcellin, Patrick
    Jensen, Donald M.
    Roberts, Stuart K.
    Hadziyannis, Stephanos J.
    Dore, Gregory J.
    Diago, Moises
    Weltman, Martin
    McCaughan, Geoffrey W.
    Cheng, Wendy
    Crawford, Darrell H.
    Sievert, William
    Rawlinson, William
    Solsky, Jonathan
    Tietz, Andreas
    Rizzetto, Mario
    HEPATOLOGY, 2009, 50 (04) : 1030A - 1031A
  • [28] ANTIVIRAL ACTIVITY AND SAFETY OF ITMN-191 IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV)
    Forestier, N.
    Larrey, D.
    Marcellin, P.
    Benhamou, Y.
    Guyader, D.
    Bradford, W.
    Porter, S.
    Patat, A.
    Rouzier, R.
    Zeuzem, S.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S35 - S35
  • [29] The impact of peginterferon (PEGIFN) and ribavirin (RBV) dosing on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) undergoing retreatment in the HALT-C trial.
    Shiffman, ML
    Morgan, TR
    Ghany, MG
    Wright, EC
    HEPATOLOGY, 2004, 40 (04) : 314A - 314A
  • [30] Effect of High-Dose Ribavirin (RBV), Alinia (Nitazoxanide) and Pegylated Interferon (pegIFN) Alfa-2a in Attaining Sustained Virologic Response (SVR) in Treatment of Chronic Hepatitis C (ERAIS-C Trial) in Naive Genotype 1 Patients
    Basu, P. Patrick
    Rayapudi, Krishna
    Pacana, Tommy
    Shah, Niraj James
    Krishnaswamy, Nithya
    Brown, Robert S.
    GASTROENTEROLOGY, 2010, 138 (05) : S218 - S218
12345